Platelet BioGenesis, a Boston, MA-based biotech startup developing a process to produce life-saving human platelets from stem cells for therapeutic applications, raised $10m in Series A financing.
The round was led by Qiming U.S. Healthcare Fund and included Vivo Capital, VI Ventures, Adena Partners, eCoast Angels, and others.
Led by Dr. Jonathan Thon, Co-Founder and incoming CEO, and Sven Karlsson, Co-Founder and Chief Business Officer, Platelet BioGenesis is a pre-clinical stage biotech company that was spun out the academic labs at Brigham and Women’s Hospital and Harvard. Platelet has developed and patented a microfluidic bioreactor and shown that functional platelets can be generated from human stem cell cultures at scale. Platelets are the “band-aids” of the blood and a critical first-line treatment for cancer and surgery.
The company was selected to participate in MassCONNECT (run by MassBio), was a 2014 MassChallenge Finalist, and has received support from the Massachusetts Life Sciences Center and the National Institutes of Health.